content: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): January 24, 2003
                                                           ----------------
  
  
                                 CYTOGEN CORPORATION
                 (Exact Name of Registrant as Specified in Charter)
  
  
            Delaware                     000-14879                  222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction    (Commission File Number)       (IRS Employer
        of Incorporation)                                      Identification No.)
  
  
  650 College Road East, 3rd Floor, Princeton, NJ                         08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                             (Zip Code)
  
  
  
                                   (609) 750-8200
                  ------------------------------------------------
                           (Registrant's telephone number,
                                including area code)
  
  
  
          -----------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
  <PAGE>
  
  
       Item 5.    Other Events and Required FD Disclosure.
  
  Product Update and Conference Call
  
       On January 24, 2003,  Cytogen  Corporation  (the "Company")  issued a press
  release   announcing  that  it  provided  DRAXIMAGE  Inc.   ("DRAXIMAGE"),   the
  radiopharmaceutical subsidiary of DRAXIS Health Inc., with notice of termination
  of each of its License and Distribution  Agreement and Product Manufacturing and
  Supply  Agreement  with  respect  to both of  DRAXIS'  BrachySeed(TM)  I-125 and
  BrachySeed(TM) PD-103 products. Cytogen provided such notice of termination upon
  a  determination  that  there  is no  reasonable  expectation  that  DRAXIS  can
  consistently supply the BrachySeed products at quantities,  activity levels, and
  schedules  amendable to commercial sale, which has negatively impacted Cytogen's
  ability to market  such  products.  Such press  release  is  attached  hereto as
  Exhibit 99.1 and is incorporated herein by reference.
  
       On January 27, 2003, the Company issued a press release  announcing that it
  will be hosting a conference call today, Monday, January 27, 2003, at 11:00 a.m.
  Eastern  Time  regarding  this  matter.   To  participate  in  the  call,   dial
  877-356-8058  or  706-643-7672.  This  call is  also  being  webcast  and can be
  accessed through the Company's website at  www.cytogen.com by selecting Investor
  Relations.  A replay of the conference call will be available on the website for
  two weeks  following  the call and an audio replay will be  available  after the
  conference  call and lasting  until  midnight,  February  25,  2003,  by calling
  800-642-1687 or 706-645-9291 and entering the conference ID number 7914576. Such
  press release is attached hereto as Exhibit 99.2 and is  incorporated  herein by
  reference.
  
       A copy of the script with respect to the conference call is attached hereto
  as  Exhibit  99.3  and  is  incorporated  herein  by  reference.  The  foregoing
  descriptions of such press releases are qualified in their entirety by reference
  to each such document.
  
       Item 7.   Financial Statements, Pro Forma Financial Information and
                 Exhibits.
  
       (c)   Exhibits.
  
              Exhibit No.      Description
              -----------      -----------
  
                 99.1          Press release of the Company dated January 24, 2003
  
                 99.2          Press release of the Company dated January 27, 2003
  
                 99.3          Script of conference call to be held on January 27,
                               2003
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
  
                                        Cytogen Corporation
  
  
  
                                        By:  /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  
  Date:  January 27, 2003
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "document8-k012403.txt", "description": "FORM 8-K DATED 01/24/03", "secsgml_size_bytes": 4733}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "03525084"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): January 24, 2003
                                                           ----------------
  
                                 CYTOGEN CORPORATION
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                     000-14879                  222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction    (Commission File Number)       (IRS Employer
        of Incorporation)                                      Identification No.)
  
  650 College Road East, 3rd Floor, Princeton, NJ                         08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                             (Zip Code)
  
                                   (609) 750-8200
                  ------------------------------------------------
                           (Registrant's telephone number,
                                including area code)
  
          -----------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  Item 5.    Other Events and Required FD Disclosure.
  
  Product Update and Conference Call
  
       On January 24, 2003,  Cytogen  Corporation  (the "Company")  issued a press
  release   announcing  that  it  provided  DRAXIMAGE  Inc.   ("DRAXIMAGE"),   the
  radiopharmaceutical subsidiary of DRAXIS Health Inc., with notice of termination
  of each of its License and Distribution  Agreement and Product Manufacturing and
  Supply  Agreement  with  respect  to both of  DRAXIS'  BrachySeed(TM)  I-125 and
  BrachySeed(TM) PD-103 products. Cytogen provided such notice of termination upon
  a  determination  that  there  is no  reasonable  expectation  that  DRAXIS  can
  consistently supply the BrachySeed products at quantities,  activity levels, and
  schedules  amendable to commercial sale, which has negatively impacted Cytogen's
  ability to market  such  products.  Such press  release  is  attached  hereto as
  Exhibit 99.1 and is incorporated herein by reference.
  
       On January 27, 2003, the Company issued a press release  announcing that it
  will be hosting a conference call today, Monday, January 27, 2003, at 11:00 a.m.
  Eastern  Time  regarding  this  matter.   To  participate  in  the  call,   dial
  877-356-8058  or  706-643-7672.  This  call is  also  being  webcast  and can be
  accessed through the Company's website at  www.cytogen.com by selecting Investor
  Relations.  A replay of the conference call will be available on the website for
  two weeks  following  the call and an audio replay will be  available  after the
  conference  call and lasting  until  midnight,  February  25,  2003,  by calling
  800-642-1687 or 706-645-9291 and entering the conference ID number 7914576. Such
  press release is attached hereto as Exhibit 99.2 and is  incorporated  herein by
  reference.
  
       A copy of the script with respect to the conference call is attached hereto
  as  Exhibit  99.3  and  is  incorporated  herein  by  reference.  The  foregoing
  descriptions of such press releases are qualified in their entirety by reference
  to each such document.
  
       Item 7.   Financial Statements, Pro Forma Financial Information and
                 Exhibits.
  
       (c)   Exhibits.
  
              Exhibit No.      Description
              -----------      -----------
  
                 99.1          Press release of the Company dated January 24, 2003
  
                 99.2          Press release of the Company dated January 27, 2003
  
                 99.3          Script of conference call to be held on January 27,
                               2003
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                        Cytogen Corporation
  
                                        By:  /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Date:  January 27, 2003